Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
Clinical trial NCT06308939 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06308939
- Sponsor
- Zhejiang Cancer Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-03-08
- Primary completion
- 2025-12-31
- Enrollment
- 81
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.